Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides B

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targete

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results

Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today ann

Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today ann

DALLAS--(BUSINESS WIRE)--Open Medicine AI is launched as separate entity by Lantern Pharma.

The study will be conducted at Rigshospitalet in Copenhagen — Denmark’s national referral center for

DALLAS--(BUSINESS WIRE)--EMA Phase 1b/2 Clinical Trial for LP-184.

The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical comp

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's

ZetaOmics introduces an autonomous "Computational Biologist" persona (agent) that performs r

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision o

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today reported clinical

Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS;

DALLAS--(BUSINESS WIRE)--Harmonic Presentation in form of 8K.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today an

In its written responses to Lantern's Type C meeting request, the FDA raised no objections to ke

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision o

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.30) per share which beat the analyst c

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Bu

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Dir

Lantern Pharma announced that it has entered into a definitive agreement for the purchase and sale o

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offerin

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report First Quarter 2026 Operating & Financial Results o

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision on

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer D

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncolo

For the first time, pharmaceutical scientists and medicinal chemists can access a unified, benchmark

The event follows the platform's scientific community debut at the American Association for Canc

Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Target

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.36) per share which beat the analyst c

Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding C

PMGC Holdings shares surged 100.6% to $3.35 in pre-market trading after announcing a licensing agree

The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with

The A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engi

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst c